Pediatric Neuroblastoma Treatment Market
Pediatric Neuroblastoma Treatment Market Study by Immunotherapy, Chemotherapy, and Others from 2023 to 2033
Analysis of Pediatric Neuroblastoma Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Market 4. Market Overview 4.1. Introduction 4.1.1. Market Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Market Analysis and Forecast, 2023–2033 4.4.1. Market Revenue Projections (US$ Mn) 4.5. Porter’s Five Force Analysis 5. Market Outlook 5.1. Epidemiology Pediatric Neuroblastoma 5.2. Pipeline Analysis 5.3. Key Unmet Needs in the Market 5.4. Global Market: Rate of Metastasis in Neuroblastoma 5.5. Global Market: Neuroblastoma Relapse/Refractory cases 5.6. Rate of Utilization of MIBG-131 6. Global Market Analysis and Forecast, by Therapy Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Therapy Type, 2023–2033 6.3.1. Immunotherapy 6.3.2. Chemotherapy 6.3.3. Others 6.4. Market Attractiveness, by Therapy Type 7. Global Market Analysis and Forecast, by End-user 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Distribution Channel, 2023–2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies & Drug Stores 7.4. Market Attractiveness, by Distribution Channel 8. Global Market Analysis and Forecast, by Region 8.1. Key Findings 8.2. Market Value Forecast, by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Rest of the World 8.3. Market Attractiveness, by Region 9. North America Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. Market Value Forecast, by Therapy Type, 2023–2033 9.2.1. Immunotherapy 9.2.2. Chemotherapy 9.2.3. Others 9.3. Market Value Forecast, by Distribution Channel, 2023–2033 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies & Drug Stores 9.4. Market Value Forecast, by Country, 2023–2033 9.4.1. U.S. 9.4.2. Canada 9.5. Market Attractiveness Analysis 9.5.1. By Therapy Type 9.5.2. By Distribution Channel 9.5.3. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast, by Therapy Type, 2023–2033 10.2.1. Immunotherapy 10.2.2. Chemotherapy 10.2.3. Others 10.3. Market Value Forecast, by Distribution Channel, 2023–2033 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies & Drug Stores 10.4. Market Value Forecast, by Country/Sub-region, 2023–2033 10.4.1. Germany 10.4.2. U.K. 10.4.3. France 10.4.4. Rest of Europe 10.5. Market Attractiveness Analysis 10.5.1. By Therapy Type 10.5.2. By Distribution Channel 10.5.3. By Country/Sub-region 11. Rest of the World Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Therapy Type, 2023–2033 11.2.1. Immunotherapy 11.2.2. Chemotherapy 11.2.3. Others 11.3. Market Value Forecast, by Distribution Channel, 2023–2033 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies & Drug Stores 11.4. Market Attractiveness Analysis 11.4.1. By Therapy Type 11.4.2. By Distribution Channel 12. Company Profiles 12.1. United Therapeutics Corporation 12.1.1. Company Overview (HQ, Business Segments, Employee Strength) 12.1.2. Product Portfolio 12.1.3. SWOT Analysis 12.1.4. Financial Overview 12.1.5. Strategic Overview 12.2. APEIRON Biologics AG 12.2.1. Company Overview (HQ, Business Segments, Employee Strength) 12.2.2. Product Portfolio 12.2.3. SWOT Analysis 12.2.4. Financial Overview 12.2.5. Strategic Overview 12.3. Baxter 12.3.1. Company Overview (HQ, Business Segments, Employee Strength) 12.3.2. Product Portfolio 12.3.3. SWOT Analysis 12.3.4. Financial Overview 12.3.5. Strategic Overview 12.4. Cellectar Biosciences, Inc. 12.4.1. Company Overview (HQ, Business Segments, Employee Strength) 12.4.2. Product Portfolio 12.4.3. SWOT Analysis 12.4.4. Financial Overview 12.4.5. Strategic Overview 12.5. Pfizer, Inc. 12.5.1. Company Overview (HQ, Business Segments, Employee Strength) 12.5.2. Product Portfolio 12.5.3. SWOT Analysis 12.5.4. Financial Overview 12.5.5. Strategic Overview 12.6. MacroGenics, Inc. 12.6.1. Company Overview (HQ, Business Segments, Employee Strength) 12.6.2. Product Portfolio 12.6.3. SWOT Analysis 12.6.4. Financial Overview 12.6.5. Strategic Overview 12.7. Bayer AG 12.7.1. Company Overview (HQ, Business Segments, Employee Strength) 12.7.2. Product Portfolio 12.7.3. SWOT Analysis 12.7.4. Financial Overview 12.7.5. Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: List of acronyms used in the report
Table 02: Global Market: Pipeline Analysis
Table 03: Global Market: Pipeline Analysis
Table 04: Global Market: Pipeline Analysis
Table 05: Global Market: Pipeline Analysis
Table 06: Global Market: Pipeline Analysis
Table 07: Global Market: Pipeline Analysis
Table 08: Global Market: Pipeline Analysis
Table 09: Global Market: Pipeline Analysis
Table 10: Global Market: Pipeline Analysis
Table 11: Global Market: Pipeline Analysis
Table 12: Global Market: Pipeline Analysis
Table 13: Global Market: Pipeline Analysis
Table 14: Global Market: Pipeline Analysis
Table 15: Global Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 16: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 17: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033
Table 18: North America Market Value (US$ Mn) Forecast, by Country, 2023–2033
Table 19: North America Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 20: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 22: Europe Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 23: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 24: Rest of the World Market Value (US$ Mn) Forecast, by Therapy Type, 2023–2033
Table 25: Rest of the World Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market
Figure 02: Global Market Size (US$ Mn), by Therapy Type, 2022
Figure 03: Global Market Segments with Leading Market Share (%), 2022
Figure 04: Global Market Value (US$ Mn) Forecast, 2023–2033
Figure 05: Global Market Value Share (%), by Therapy Type, 2022
Figure 06: Global Market Value Share (%), by Distribution Channel, 2022
Figure 07: Global Market Value Share (%), by Region, 2022
Figure 08: Key Industry Events
Figure 09: Porter’s Five Forces Analysis
Figure 10: Epidemiology of Neuroblastoma
Figure 11: Epidemiology of Neuroblastoma: Numbers of Annual New Neuroblastoma Cases in Key Markets
Figure 12: Epidemiology of Neuroblastoma Key Research Findings
Figure 13: Epidemiology of Neuroblastoma, by Country
Figure 14: Epidemiology of Neuroblastoma, by Country
Figure 15: Epidemiology of Neuroblastoma, by Country
Figure 16: Key Unmet Needs in the Market
Figure 17: Global Market: Rate of Metastasis to the Brain
Figure 18: Global Market: Rate of Metastasis to the Brain
Figure 19: Global Market: Neuroblastoma Relapse/Refractory cases
Figure 20: Global Market: Neuroblastoma Relapse/Refractory cases
Figure 21: Global Market: Utilization of MIBG-131
Figure 22: Global Market: Utilization of MIBG-131
Figure 23: Global Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 24: Global Market Attractiveness, by Therapy Type, 2023–2033
Figure 25: Global Market Revenue (US$ Mn) Forecast, by Immunotherapy, 2023–2033
Figure 26: Global Market Revenue (US$ Mn) Forecast, by Chemotherapy, 2023–2033
Figure 27: Global Market Revenue (US$ Mn) Forecast, by Others, 2023–2033
Figure 28: Global Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 29: Global Market Attractiveness, by Distribution Channel, 2023–2033
Figure 30: Global Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2023–2033
Figure 31: Global Market Revenue (US$ Mn) Forecast, by Retail Pharmacies &Drug Stores, 2023–2033
Figure 32: Global Market Value Share (%), by Region, 2023 and 2033
Figure 33: Global Market Attractiveness, by Region, 2023–2033
Figure 34: North America Market Revenue (US$ Mn) forecast, 2023–2033
Figure 35: North America Market Value Share (%), by Country, 2023 and 2033
Figure 36: North America Market Attractiveness, by Country, 2023–2033
Figure 37: North America Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 38: North America Market Attractiveness, by Therapy Type, 2023–2033
Figure 39: North America Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 40: North America Market Attractiveness, by Distribution Channel, 2023–2033
Figure 41: Europe Market Revenue (US$ Mn) Forecast, 2023–2033
Figure 42: Europe Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 43: Europe Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 44: Europe Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 45: Europe Market Attractiveness, by Therapy Type, 2023–2033
Figure 46: Europe Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 47: Europe Market Attractiveness, by Distribution Channel, 2023–2033
Figure 48: Rest of the World Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 49: Rest of the World Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 50: Rest of the World Market Attractiveness, by Therapy Type, 2023–2033
Figure 51: Rest of the World Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 52: Rest of the World Market Attractiveness, by Distribution Channel, 2023–2033
Figure 53: United Therapeutics Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 54: United Therapeutics Corporation Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 55: United Therapeutics Corporation Breakdown of Net Sales, by Product, 2022
Figure 56: United Therapeutics Corporation Research and Development Cost (US$ Mn), 2018–2022
Figure 57: United Therapeutics Corporation: SWOT Analysis
Figure 58: MacroGenics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 59: MacroGenics, Inc. Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 60: MacroGenics, Inc. Net sales (US$ Mn) by key brands
Figure 61: MacroGenics, Inc. Research and Development Cost (US$ Mn), 2018–2022
Figure 62: MacroGenics, Inc.: SWOT Analysis
Figure 63: APEIRON Biologics AG: SWOT Analysis
Figure 64: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2022
Figure 65: Baxter Breakdown of Net Sales (%), by Region, 2022
Figure 66: Baxter pipeline of generic products, 2018–2023
Figure 67: Baxter: SWOT Analysis
Figure 68: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 69: Pfizer Inc. R&D Expenses (US$ Mn), 2018–2022
Figure 70: Pfizer Inc.: SWOT Analysis
Figure 71: Cellectar Biosciences, Inc. Research and Development Cost (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 72: Cellectar Biosciences, Inc.: SWOT Analysis
Figure 73: Bayer Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 74: Bayer Group Breakdown of Net Sales (%), by Region, 2022
Figure 75: Bayer Group Breakdown of Net Sales (%), by Business Segment, 2022
Figure 76: Bayer Group: SWOT Analysis
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request